

Francesco Schettini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/746970/publications.pdf>

Version: 2024-02-01

55
papers

1,818
citations

394421

19
h-index

289244

40
g-index

58
all docs

58
docs citations

58
times ranked

2271
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	5.2	331
2	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	5.0	175
3	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 608.	2.8	160
4	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	10.7	131
5	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
6	Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. <i>Cancer Treatment Reviews</i> , 2016, 46, 20-26.	7.7	87
7	Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. <i>Cancer Treatment Reviews</i> , 2016, 50, 129-141.	7.7	81
8	Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. <i>Menopause</i> , 2016, 23, 1108-1113.	2.0	75
9	Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. <i>Menopause</i> , 2018, 25, 657-662.	2.0	65
10	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
11	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	6.3	59
12	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.7	52
13	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. <i>EBioMedicine</i> , 2022, 75, 103801.	6.1	47
14	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	2.8	41
15	Dissecting the biological heterogeneity of HER2-positive breast cancer. <i>Breast</i> , 2021, 59, 339-350.	2.2	41
16	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018, 38, 86-91.	2.2	27
17	Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 401-409.	2.5	27
18	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2022, 16, 69-87.	4.6	24

#	ARTICLE	IF	CITATIONS
19	Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. <i>ESMO Open</i> , 2021, 6, 100102.	4.5	24
20	Effect of rescue fractional microablative CO2 laser on symptoms and sexual dysfunction in women affected by vulvar lichen sclerosus resistant to long-term use of topic corticosteroid: a prospective longitudinal study. <i>Menopause</i> , 2020, 27, 418-422.	2.0	23
21	PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom. <i>Breast Care</i> , 2017, 12, 290-294.	1.4	21
22	Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study. <i>Oncotarget</i> , 2017, 8, 115709-115717.	1.8	18
23	BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. <i>Frontiers in Oncology</i> , 2021, 11, 772052.	2.8	18
24	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	3.7	17
25	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	2.5	14
26	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. <i>Npj Breast Cancer</i> , 2021, 7, 8.	5.2	14
27	Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. <i>Frontiers in Oncology</i> , 2021, 11, 686776.	2.8	13
28	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. <i>ESMO Open</i> , 2021, 6, 100099.	4.5	12
29	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
30	Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 421-431.	2.5	9
31	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021, 69, 103451.	6.1	7
32	De novo metastatic breast cancer arising in young women: review of the current evidence. <i>Clinical Breast Cancer</i> , 2021, , .	2.4	6
33	14-gene immunoglobulin (IGC) and proliferation signatures and association with overall survival across cancer-types.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2636-2636.	1.6	6
34	Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. <i>Future Oncology</i> , 2020, 16, 1629-1637.	2.4	5
35	Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues. <i>Breast Journal</i> , 2019, 25, 1310-1311.	1.0	4
36	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020, 50, 56-63.	2.2	4

#	ARTICLE	IF	CITATIONS
37	The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 832-836.	1.7	3
38	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017, 8, 112816-112824.	1.8	3
39	Abstract P1-16-01: Efficacy of endocrine- versus chemotherapy-based treatments in hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) postmenopausal metastatic breast cancer (mBC): A network meta-analysis (NMA). , 2019, , .		2
40	Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials. <i>Cancer Research</i> , 2022, 82, P4-07-08-P4-07-08.	0.9	2
41	PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis. <i>Annals of Oncology</i> , 2019, 30, v82.	1.2	1
42	Prognostic and Predictive Role of Circulating Tumor Cells. , 2019, , 181-190.		1
43	23P Clinical, pathological and gene expression features of HER2-low breast cancer. <i>Annals of Oncology</i> , 2020, 31, S24.	1.2	1
44	Abstract P5-11-18: Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2- metastatic breast cancer patients: The PALPract study. , 2020, , .		1
45	Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.. <i>Journal of Clinical Oncology</i> , 2018, 36, 542-542.	1.6	1
46	Palbociclib added to ongoing endocrine therapy for hormone receptor- positive HER2- negative metastatic breast cancer: A case report series. <i>Molecular and Clinical Oncology</i> , 2020, 12, 456-460.	1.0	1
47	Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?. <i>Oncology</i> , 2021, , .	1.9	1
48	5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i). <i>Annals of Oncology</i> , 2020, 31, S17.	1.2	0
49	168P Development of a combined clinical model to predict progression-free survival (PFS) in advanced breast cancer (ABC) treated with CDK4/6 inhibitors (CDK4/6i). <i>Annals of Oncology</i> , 2020, 31, S76.	1.2	0
50	Endocrine Therapy. <i>UNIPA Springer Series</i> , 2021, , 169-180.	0.1	0
51	Metastatic Breast Cancer. <i>UNIPA Springer Series</i> , 2021, , 467-479.	0.1	0
52	Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 640-640.	1.6	0
53	A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 539-539.	1.6	0
54	Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12528-e12528.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Abstract P3-09-03: Single nucleotide polymorphisms of aromatase gene (<i>CYP19A1</i>) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study. Cancer Research, 2022, 82, P3-09-03-P3-09-03.	0.9	0